Mereo BioPharma Group PLC (MREO) FinancialsMREOMereo BioPharma Group PLC

Evaluating the bottom line, Mereo BioPharma Group PLC maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -67.85%, provide a clear picture of how effectively MREO converts its operational activities into shareholder value.

In the context of the broader market, MREO competes directly with industry leaders such as TIL and IMA. With a market capitalization of $45.19M, it holds a significant position in the sector. When comparing efficiency, MREO's gross margin of N/A stands against TIL's N/A and IMA's N/A. Such benchmarking helps identify whether Mereo BioPharma Group PLC is trading at a premium or discount relative to its financial performance.

Mereo BioPharma has shown a gross margin of 73.60% in Q2 2025, but its total revenue for Q4 2024 was $0.00, indicating a lack of consistent revenue generation.